Surgical Safety Technologies delivers data-driven AI technology to hospitals for safe surgeries. It empowers surgeons with an objective assessment of technical and non-technical proficiency using academically validated frameworks.
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Geneos Therapeutics, Inc. specializes in the production and development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and based in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are specifically tailored to the unique tumor mutations of each patient. By identifying relevant neoantigen targets from individual tumors, Geneos aims to develop innovative treatments that provide targeted immunotherapies for cancer patients, enhancing the potential for effective disease management and cure.
Provider of patient-centric cancer care services intended to support community oncologists and healthcare systems. The company's services provide scalable and effective delivery of low-cost cancer care across multiple care sites, enabling patients to receive cancer treatment and supportive care at home.
Access Optics specializes in the manufacturing of precision and micro-scale optics tailored for applications in tiny cameras and medical equipment, particularly endoscopic devices. The company combines innovative engineering, process development, and optical fabrication with advanced coating technologies to create high-performance optical assemblies and micro-scale surgical imaging products. Designed to withstand extreme pressures, temperatures, and humidity, these products include hermetic seals that enhance the reliability of medical instruments. Access Optics' commitment to pioneering product development and advanced materials solutions has positioned it as a key supplier for leading original equipment manufacturers in sectors such as endoscopy, dermatology, aerospace, and chromatography, ultimately contributing to improved surgical outcomes.
CryOSA, Inc., a medical device company, develops novel treatments for patients with sleep disordered breathing. It offers therapies for obstructive sleep apnea. CryOSA, Inc. was incorporated in 2014 and is based in Roseville, Minnesota.
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Geneos Therapeutics, Inc. specializes in the production and development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and based in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are specifically tailored to the unique tumor mutations of each patient. By identifying relevant neoantigen targets from individual tumors, Geneos aims to develop innovative treatments that provide targeted immunotherapies for cancer patients, enhancing the potential for effective disease management and cure.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
KēlaHealth is a software platform that combines predictive algorithms with high-impact interventions to reduce surgical complications. They use millions of data points to inform each patient's comprehensive risk profile, then recommend the best interventions to mitigate those risks. By following every surgical journey end-to-end, from prediction and action to outcomes, they continuously improve and inform the surgical quality ecosystem.
Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.
CryOSA, Inc., a medical device company, develops novel treatments for patients with sleep disordered breathing. It offers therapies for obstructive sleep apnea. CryOSA, Inc. was incorporated in 2014 and is based in Roseville, Minnesota.
Glyscend, Inc. is a biotechnology company focused on developing innovative therapies for metabolic diseases, particularly type 2 diabetes. Founded in 2014 and based in Baltimore, Maryland, Glyscend aims to provide a non-invasive treatment option that mimics the metabolic benefits of bariatric surgery without the need for invasive procedures. The company's core technology is an orally ingestible intestinal coating that targets the duodenum, inhibiting key neurohormonal pathways to help regulate glucose levels effectively. This approach not only seeks to improve patient outcomes by addressing diabetes directly but also aims to minimize common side effects associated with traditional treatments, such as weight gain and hypoglycemia. Glyscend is committed to equipping healthcare providers with effective tools for treating diabetes, moving beyond mere management of the disease.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
Remedy Applications Inc., known as Remedy, is a healthcare technology company based in Austin, Texas, founded in 2015. The company specializes in on-demand urgent and primary care services, offering innovative delivery methods for healthcare. Remedy provides 24/7 telemedicine, nurse access, lab visits, and house calls, allowing individual patients and large employer clients to receive quality medical care at home. Its software facilitates the booking of healthcare professionals, including nurses and doctors, who are registered with the company, to conduct regular checkups and provide necessary treatment. Through its services, Remedy aims to make healthcare more accessible and affordable for patients.
Geneos Therapeutics, Inc. specializes in the production and development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and based in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are specifically tailored to the unique tumor mutations of each patient. By identifying relevant neoantigen targets from individual tumors, Geneos aims to develop innovative treatments that provide targeted immunotherapies for cancer patients, enhancing the potential for effective disease management and cure.
Endogenex
Series A in 2018
DyaMX is developing therapies for GI and metabolic disease processes.
Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
CryOSA, Inc., a medical device company, develops novel treatments for patients with sleep disordered breathing. It offers therapies for obstructive sleep apnea. CryOSA, Inc. was incorporated in 2014 and is based in Roseville, Minnesota.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Claret Medical, Inc. is a cardiovascular medical device company that specializes in developing cerebral vascular protection systems for transcatheter aortic valve implantation and various endovascular procedures. Its flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris that may be dislodged during these procedures. Additionally, the company offers small 6 French catheters that are inserted through an artery in the patient's right arm and guided toward the heart, facilitating the protection of the cerebral vascular system from potential embolic material. Founded in 2009 and based in Santa Rosa, California, Claret Medical operates as a subsidiary of Boston Scientific Corporation, focusing on enhancing patient safety during interventional cardiovascular treatments.
Millipede Inc. is a medical technology company based in Santa Rosa, California, focused on developing catheter-based solutions for the treatment of mitral and tricuspid regurgitation. Founded in 2012, the company designs a semi-rigid annuloplasty ring that aims to replicate the gold standard in valve repair. This innovative solution helps restore the health of patients by reducing the valve annulus diameter, which facilitates the return of leaflet coaptation and alleviates severe mitral regurgitation. As of early 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, expanding options for physicians and patients globally.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.
Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
Lyric Pharmaceuticals Inc. is a clinical-stage pharmaceutical company founded in 2013 and based in South San Francisco, California. The company focuses on developing novel gastrointestinal therapeutics aimed at addressing unmet medical needs in critically ill and hospitalized patients. One of its primary products, ulimorelin, is a macrocyclic agonist of the hormone ghrelin, being developed as LP101 for the treatment of enteral feeding intolerance and other gastrointestinal disorders in the intensive care unit. Lyric's portfolio includes pro-kinetic and pro-metabolic drugs designed to improve patient care in hospital settings.
Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Claret Medical, Inc. is a cardiovascular medical device company that specializes in developing cerebral vascular protection systems for transcatheter aortic valve implantation and various endovascular procedures. Its flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris that may be dislodged during these procedures. Additionally, the company offers small 6 French catheters that are inserted through an artery in the patient's right arm and guided toward the heart, facilitating the protection of the cerebral vascular system from potential embolic material. Founded in 2009 and based in Santa Rosa, California, Claret Medical operates as a subsidiary of Boston Scientific Corporation, focusing on enhancing patient safety during interventional cardiovascular treatments.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Ketra, a subsidiary of Lutron Electronics Co., Inc., specializes in manufacturing high-performance LED lighting and integrated control systems for both residential and commercial applications. Founded in 2009 and headquartered in Austin, Texas, the company offers a comprehensive range of products, including various luminaires, lamps, and control systems, such as keypads and mobile applications. Ketra is recognized for its innovative approach to lighting, providing products that enhance natural light environments and improve user well-being. Its full-stack lighting solutions feature advanced technologies that ensure color stability and uniform intensity, promoting better sleep, productivity, and overall health. By delivering a cohesive system of lighting fixtures, controls, and software, Ketra simplifies installation and offers a versatile lighting solution that meets diverse needs.
Ketra, a subsidiary of Lutron Electronics Co., Inc., specializes in manufacturing high-performance LED lighting and integrated control systems for both residential and commercial applications. Founded in 2009 and headquartered in Austin, Texas, the company offers a comprehensive range of products, including various luminaires, lamps, and control systems, such as keypads and mobile applications. Ketra is recognized for its innovative approach to lighting, providing products that enhance natural light environments and improve user well-being. Its full-stack lighting solutions feature advanced technologies that ensure color stability and uniform intensity, promoting better sleep, productivity, and overall health. By delivering a cohesive system of lighting fixtures, controls, and software, Ketra simplifies installation and offers a versatile lighting solution that meets diverse needs.
Ketra, a subsidiary of Lutron Electronics Co., Inc., specializes in manufacturing high-performance LED lighting and integrated control systems for both residential and commercial applications. Founded in 2009 and headquartered in Austin, Texas, the company offers a comprehensive range of products, including various luminaires, lamps, and control systems, such as keypads and mobile applications. Ketra is recognized for its innovative approach to lighting, providing products that enhance natural light environments and improve user well-being. Its full-stack lighting solutions feature advanced technologies that ensure color stability and uniform intensity, promoting better sleep, productivity, and overall health. By delivering a cohesive system of lighting fixtures, controls, and software, Ketra simplifies installation and offers a versatile lighting solution that meets diverse needs.
Guided Interventions is a Cleveland-based medical device startup Led by CEO Dr. Matthew Pollman, Guided Interventions develops a a fractional flow reserve (FFR) guidewire that is designed to provide an effective way to obtain FFR measurements during coronary catheterization procedures. It is optimized for improved maneuverability and handling.
Rise Health, Inc. is a healthcare services company based in Chicago, Illinois, that specializes in providing primary care solutions to physician practices and healthcare organizations across the United States. The company focuses on enhancing patient access to primary care and improving the care experience by enabling patients to engage effectively with their primary care providers. Rise Health equips physicians with essential tools and support to manage their patients' health more efficiently, optimizing the use of their time and skills. Additionally, the company assists clients in developing the necessary infrastructure to participate in accountable care organizations and adhere to the principles of patient-centered medical homes. Founded in 2009, Rise Health was previously known as Optizend, Inc.
Rise Health, Inc. is a healthcare services company based in Chicago, Illinois, that specializes in providing primary care solutions to physician practices and healthcare organizations across the United States. The company focuses on enhancing patient access to primary care and improving the care experience by enabling patients to engage effectively with their primary care providers. Rise Health equips physicians with essential tools and support to manage their patients' health more efficiently, optimizing the use of their time and skills. Additionally, the company assists clients in developing the necessary infrastructure to participate in accountable care organizations and adhere to the principles of patient-centered medical homes. Founded in 2009, Rise Health was previously known as Optizend, Inc.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Healthcare Highways, Inc. is an accountable care organization and health plan based in Frisco, Texas, founded in 2010 by Michael Wilson. The company collaborates with hospitals, providers, employers, payers, and brokers to offer customized healthcare solutions that aim to reduce costs while maintaining high-quality care. Its services include third-party administration, stop-loss coverage, disease management, pharmacy benefit management, and population health initiatives. With a focus on proactive strategies, Healthcare Highways addresses current and emerging challenges in the healthcare landscape by creating innovative plans tailored to the needs of self-insured clients. The company emphasizes the importance of facilitating a smooth transition for consumers and employers in a complex healthcare environment, ultimately striving to deliver sustainable value and improved healthcare outcomes for all stakeholders involved.
Healthcare Highways, Inc. is an accountable care organization and health plan based in Frisco, Texas, founded in 2010 by Michael Wilson. The company collaborates with hospitals, providers, employers, payers, and brokers to offer customized healthcare solutions that aim to reduce costs while maintaining high-quality care. Its services include third-party administration, stop-loss coverage, disease management, pharmacy benefit management, and population health initiatives. With a focus on proactive strategies, Healthcare Highways addresses current and emerging challenges in the healthcare landscape by creating innovative plans tailored to the needs of self-insured clients. The company emphasizes the importance of facilitating a smooth transition for consumers and employers in a complex healthcare environment, ultimately striving to deliver sustainable value and improved healthcare outcomes for all stakeholders involved.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.
Rex Bionics Ltd. is a New Zealand-based company that specializes in the development and manufacturing of robotic medical equipment aimed at rehabilitation. Incorporated in 2007, the company produces the REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Rex Bionics focuses on improving the physical and psychological well-being of people affected by spinal cord injuries, strokes, traumatic brain injuries, and neurodegenerative diseases. The company's primary products include the REX and the REX P (Personal), which cater to both professional neuro-rehabilitation clinics and personal homecare markets. Through innovative technology, Rex Bionics aims to enhance the rehabilitation experience for individuals facing significant mobility challenges.
At AbVitro, they are committed to advancing the treatment of poorly understood human diseases with an underlying immune component. Their mission is to harness the power of the human immune system and its role in complex diseases to uncover new potential therapeutic targets or biomarkers, while simultaneously discovering and evaluating their respective fully human antibody binders for therapeutic potential. Simply put, They find new therapeutic targets with matching therapeutic antibodies and/or T cell receptors (TCRs) in diseases with unmet medical needs.
LumaTherm
Series A in 2012
LumaTherm, Inc.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Millipede Inc. is a medical technology company based in Santa Rosa, California, focused on developing catheter-based solutions for the treatment of mitral and tricuspid regurgitation. Founded in 2012, the company designs a semi-rigid annuloplasty ring that aims to replicate the gold standard in valve repair. This innovative solution helps restore the health of patients by reducing the valve annulus diameter, which facilitates the return of leaflet coaptation and alleviates severe mitral regurgitation. As of early 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, expanding options for physicians and patients globally.
Explorys, Inc. is a healthcare cloud-computing platform based in Cleveland, Ohio, established in 2009. The company specializes in enterprise performance management for integrated healthcare systems in the United States, offering solutions for data management, business intelligence, and population analytics. Its platform allows healthcare systems to collect and integrate diverse data types, including clinical, claims, and billing information, facilitating improved quality of care and operational efficiency. By serving providers, payers, and life sciences organizations, Explorys aims to enhance treatment outcomes and accelerate research and product development. The company's services are delivered through software-as-a-service and platform-as-a-service models, supporting critical measurement for healthcare reform and performance management. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.
Explorys, Inc. is a healthcare cloud-computing platform based in Cleveland, Ohio, established in 2009. The company specializes in enterprise performance management for integrated healthcare systems in the United States, offering solutions for data management, business intelligence, and population analytics. Its platform allows healthcare systems to collect and integrate diverse data types, including clinical, claims, and billing information, facilitating improved quality of care and operational efficiency. By serving providers, payers, and life sciences organizations, Explorys aims to enhance treatment outcomes and accelerate research and product development. The company's services are delivered through software-as-a-service and platform-as-a-service models, supporting critical measurement for healthcare reform and performance management. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Rise Health, Inc. is a healthcare services company based in Chicago, Illinois, that specializes in providing primary care solutions to physician practices and healthcare organizations across the United States. The company focuses on enhancing patient access to primary care and improving the care experience by enabling patients to engage effectively with their primary care providers. Rise Health equips physicians with essential tools and support to manage their patients' health more efficiently, optimizing the use of their time and skills. Additionally, the company assists clients in developing the necessary infrastructure to participate in accountable care organizations and adhere to the principles of patient-centered medical homes. Founded in 2009, Rise Health was previously known as Optizend, Inc.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
Protein Discovery, Inc. is a life sciences company specializing in the development and commercialization of innovative sample preparation technologies for protein and peptide analysis via mass spectrometry. The company offers several key products, including the Gelfree 8100 fractionation system, which separates complex protein mixtures into liquid-phase molecular weight fractions, and the Passport 1200 sample preparation system, designed to enrich low molecular weight proteins and peptides while eliminating matrix interferences, facilitating high-throughput quantification. Additionally, Protein Discovery provides the PPS Silent Surfactant, a reagent that solubilizes membrane proteins and reduces detergent interference. The UPX universal protein extraction kit is also available for detergent extraction of proteins from cells and tissues. Catering to life science researchers and drug development scientists, Protein Discovery markets its products both through Agilent Technologies and online, reaching a global audience. Founded in 2001 in Knoxville, Tennessee, the company was originally named Qgenics Biosciences, Inc. before rebranding to its current name in 2004.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.